Vendor Intelligence Report: Nanjing Xiyuxun Technology XYX

Published 13 Jun 2026. 22-page investigative report on who is behind Nanjing Xiyuxun Technology XYX: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, XYX recorded 4 pass / 0 fail for a 100% overall pass rate. The sample base is narrow, covering only GHK-Cu and Retatrutide. GHK-Cu is the cleaner tested choice; Retatrutide passes but is more sensitive under stricter grading, making batch-matched COAs, visible vial identifiers and independent retesting the key buyer controls.

Platform records pull the story back to earth. The Made-in-China company table describes Nanjing Xiyuxun Technology as a 2024-founded Trader, not a documented peptide manufacturer. Its TÜV Rheinland badge verifies a platform supplier audit, not GMP or product quality, and archive records sit uneasily beside manufacturer-style and long-history marketing language.

The investigation maps an XCE/PGB/XYX-adjacent supply trail without overstating it. Forum artifacts, forum-recorded XCE shutdown timing and a PGB-style batch identifier on an XYX-attributed sample point toward product-flow continuity, while formal ownership succession remains unresolved. Product listings add customs and authenticity concerns through GLP-1 brand strings, Janoshik testing claims, safe-delivery language and an explicit disguise option.

Reputation evidence is platform-bound and mixed: repeated Made-in-China five-star text across countries, one-star communication complaints and the Jackdilen / Wei Zhang sales persona. The buyer read is not blanket avoidance; it is batch-by-batch caution for a trader with passing results on two tested products and no Finnrick basis to extrapolate across the catalog.

Inside the full report:

  • Finnrick pass/fail detail, product ratings and methodology-divergence charts for GHK-Cu and Retatrutide
  • Made-in-China profile history, company table, review screenshots and TÜV certificate MIC-ASI2441363 analysis
  • XCE shutdown to XYX emergence to PGB-sourcing timeline, with forum artifacts and batch-identifier evidence
  • Catalog/shipping screenshots covering Mounjaros/Wegovys/Zepbound strings, Janoshik claims, safe delivery and disguise language
  • Regulatory context and unresolved leads: DOJ Watkins, CBP seizures, Jiangsu registry gaps, XCE succession and Cocer branding

Risk assessment

  • Supply-chain enforcement exposure — high: Evidence suggests an XCE/PGB-adjacent channel, while DOJ/CBP actions show active misbranded-peptide scrutiny; XYX is not named in the DOJ release.
  • Retatrutide-specific quality margin risk — medium: Retatrutide is 2/2 pass at 80.84%, but trails GHK-Cu's 90% and is more methodology-sensitive; verify each batch.
  • Corporate-identity and manufacturer-claim risk — medium: Platform records show a 2024-founded Trader with one foreign trading staff; '10 years', GMP and QA/QC claims were not verified.
  • Customs and disguised-shipping risk — medium: Listings use GLP-1 brand-name strings and offer 'safe delivery' / 'Disguise: Can provide', raising seizure and compliance risk.
  • Review-authenticity risk — medium: Made-in-China reviews include duplicated 5-star text across countries plus three 1-star communication complaints.